No abstract available.
Insulin-Like Growth Factor I*

No abstract available.
Insulin-Like Growth Factor I ; Nutrition Assessment

No abstract available.
Child* ; Growth Hormone* ; Humans ; Insulin* ; Insulin-Like Growth Factor I*

No abstract available.
Gene Expression* ; Humans* ; Insulin-Like Growth Factor I* ; Thyroid Gland*

No abstract available.
Child* ; Humans ; Insulin-Like Growth Factor I* ; Plasma* ; Somatomedins*

OBJECTIVETo investigate the diagnostic value of insulin like growth factor I(IGF-I), β2-microglobulin (β2MG) and serum ferritin (SF) in patients with multiple myeloma (MM) and their ralationship with clinical staging.

METHODSSeventy-seven patients with MM treated in Depertment of Hematology of Shanghai 10th hospital and Oncology of Shanghai Armed Police Hospital from August 2016 to June 2017 were enrolled in MM group, at same period 77 healthy volunteers were enrolled in normal control group. The diagnostic value of IGF-I, β2-MG and SF for MM, and their levels in different stages of MM were compared.

RESULTSThe ROC analysis showed that β2-MG and SF alone as well as their combination had the diagnostic significance for MM, moreover the diagnostic value of IGF-I, β2-MG and SF combination was highest, but the single IGF-I did not possess diagnostic significance for MM. The comparison of IGF-I, β2-MG and SF levels in different stages of MM showed that the β2-MG and SF levels in I stage were higher than those in normal control group (P<0.05), but lower than those in II and III stages (P<0.05). The IGF-I level in I stage was not statistically and significantly different from IGF-I level in normal control group (P>0.05), but lower than those in II and III stage (P<0.05). The relationship analysis between IGF-I and β2-MG, SF in different stages showed that the IGF-I related with SF in I stage (r=0.417), but did not relate with β2-MG; the IGF-I in II stage related with β2-MG and SF in II stage (r=0.543, r=0.426); IGF-I related with β2-MG and SF in III stage (r=0.425 and r=0.672).

CONCLUSIONThe diagnostic value of IGF-I, β2-MG and SF alone does not high for MM, but their combination can significantly enhance the occurate rate of MM diagnosis. The levels of IGF-I, β2-MG and SF in II and III stages of MM all increase, moreover the level of IGF-I correlates with the levels of β2-MG and SF.

OBJECTIVE: The purpose of this study was to investigate possible menopause related changes in circulating insulin-like growth factor binding protein 3 (IGFBP-3) levels and their relationship with insulin-like growth factor 1 (IGF-1) plasma levels, osteocalcin(Ost) and urinary deoxypyridinoline(Dpd) in either surgical menopause or natural menopause, METHOD: Seventy-two postmenopausal women (surgical menopause 48, natural menopause 24) were invited to participate in this study. In all subjects plasma IGF-1 and IGFBP-3 levels were measSURED by radioimmunoassay and Ost and Dpd were measured by enzyme linked immunosorbent assay(ELISA). RESULTS: No difference was found between mean IGFBP-3 plasma levels in the two groups studied(3,522 +/- 926 vs 3,854 +/- 569 ng/ml), while mean IGF-1 levels were significantly lower in natural menopause as compared with surgical menopause (natural 126 +/- 44 vs surgical 163 +/- 66 ng/ml, p=0.007). No difference was found between mean Ost levels in the two groups studied (natural menopause 8.0 +/- 2.9 vs surgical menopause 8,9 +/- 2.1 ng/ml, p=0.113) and mean Dpd levels in the two studied (natural menopause 6.8 +/- 2.3 vs surgical menopause 7.8 +/- 3.4 mM, p=0.213). CONCLUSION: IGF-1 was significantly lower in natural menopause as compared with surgical menopause, but no significant difference was found in IGFBP-3, Ost, and Dpd levels
Biomarkers* ; Carrier Proteins* ; Female ; Humans ; Insulin* ; Insulin-Like Growth Factor Binding Protein 3 ; Insulin-Like Growth Factor Binding Proteins* ; Insulin-Like Growth Factor I ; Menopause* ; Osteocalcin* ; Plasma ; Radioimmunoassay

In the thyroid tissue, thyrotrophin(TSH) and IGF-I played major role of the goitrogen. But the evidences and precise mechanism of these two factors were not known so much. Actually local secretion of thyroid IGF-I was originated from its fibroblasts mainly. We guessed major roles of IGFs in the thyroid tissue were local paracrine effect of thyroid cells proliferation and differentiation which concert with TSH. Recently, some reporters described the source of thyroid IGF-I were partly from thyroid follicular cells and its action were synergistic with TSH. We measured TSH, IGF-I and IGFBP-3 from sera and thyroid cystic fluids in 36 patients with simple thyroid cyst and examined into correlation between TSH, IGF-I and IGFBP-3.1) According to cyst/serum TSH ratio, we classified two groups(Group I; c/s TSH <1, n=19. Group II; c/s TSH >1, n=17). This classification criteria means that cystic TSH level were increased than that of serum or not.2) The serum TSH, IGF-I and IGFBP-3 levels are not difference between group I and II.3) Cystic TSH were dependent on the serum TSH in Group I, but negative correlation in Group II. In Group II, cystic TSH was significant increased.4) Serum IGF-I were positive correlation in each Group5) In Group II, cystic IGF-I was not exceed than those of serum IGF-I, but some cystic IGFBP-3 were more increased than those of serum.6) In Group II, cystic IGFBP-3 increased than serum TSH, and cystic IGFBP-3 was positive correlation with cystic TSH and cystic IGF-I.As these data suggested that cystic TSH and cystic IGF-I levels may influence cystic IGFBP-3 level. The main effect for maintenance of cyst was mediated by cystic TSH and cystic IGFBP-3. But the cystic IGFBP-3 has major role for thyroid cyst than cyst TSH.
Classification ; Fibroblasts ; Humans ; Insulin ; Insulin-Like Growth Factor Binding Protein 3 ; Insulin-Like Growth Factor I ; Thyroid Gland

PURPOSE: Insulin-like growth factor(IGF-I) and IGF binding protein(IGFBP)-3 is thought to play an important role in fetal erythropoiesis. The objective of this study was to establish a relation between IGF-I, free IGF-I, IGFBP-1, and -3 with hemoglobin level in healthy term, 3-month, and 12-month old infants. METHODS: Healthy term infants(n=20)were enrolled at birth, as well as 3 monthsI concentrations were measured by a specific radioimmuno-assay(RIA), and the serum levels of free IGF-I, IGFBP-1 and -3 were measured by specific immunoradiometric assay(IRMA) kit. RESULTS: The mean level of hemoglobin was 15.6+/-1.4g/dL, IGF-I was 14.5+/-7.0ng/mL and IGFBP-3 was 1205.2+/-292.1ng/mL at birth. Serum IGF-I, IGFBP-3 and hemoglobin concentrations were correlated positively at birth(P<0.01), and a positive correlation was observed between hemoglobin and free IGF-I(P<0.05). The mean level of hemoglobin was 10.7+/-0.8g/dL, IGF-I was 27.3+/-11.1 ng/mL and IGFBP-3 was 1674.1+/-399.1ng/mL at three months of age. No correlation was observed between hemoglobin and IGF-I, IGFBP-3 and free IGF-I. The mean level of hemoglobin was 10.6+/-0.8g/dL, IGF-I was 45.5+/-13.9ng/mL and IGFBP-3 was 2124.5+/-401.8ng/mL at 12 months of age. CONCLUSION: Our results show that blood hemoglobin is positively correlated to serum IGF-I and IGFBP-3 concentrations, indirectly indicating the involvement of mediators of growth hormone on the regulation of physiologic hemoglobin concentration at birth.
Erythropoiesis ; Growth Hormone ; Humans ; Infant* ; Insulin-Like Growth Factor Binding Protein 1 ; Insulin-Like Growth Factor Binding Protein 3 ; Insulin-Like Growth Factor I ; Parturition

The insulin-like growth factor-I(IGF-I) is a hormone that has growth stimulation and metabolic effects. Insulin-like growth factor binding proteins (IGFBPs) were known to be the most important factors that affect bioavailability of IGF. Thereby, the changes of IGFBPs may affect the bioavailability of IGF-I. Because growth hormone/IGF system may be affected by dialysis therapy, the changes of GH, IGF-1, IGFBPs levels after dialysis therapy can affect the bioavailability of IGF. To evaluate the changes of serum levels of IGF-I and IGFBP-3 after long-term dialysis therapy, we measured the serum IGF-I and IGFBP-3 levels in the patients on hemodialysis and on peritoneal dialysis. Eight patients undergoing peritoneal dialysis, 10 patients undergoing hemodialysis, and age-matched 10 normal control patients were studied. In patients on hemodialysis, the mean serum level of IGF-I before hemodialysis was 90.6+/-9.0 nanogram/mL, and after long-term hemodialysis was 130.9+/-31.0 nanogram/milliliter. The mean serum level of IGFBP-3 before hemodialysis was 14,549+/-7,815 microgram/liter, and after long-term hemodialysis was 5,726+/-883 microgram/liter. There were no significant changes of serum IGF-I and IGFBP-3 levels after long-term hemodialysis therapy. In patients on peritoneal dialysis, the mean serum level of IGF-I before peritoneal dialysis was 169.8+/-20.5 nanogram/milliliter, and after long-term peritoneal dialysis was 242.6+/-37.6 nanogram/mL. The mean serum level of IGFBP- 3 before peritoneal dialysis was 10,272+/-885 microgram/liter, and after ling-term peritoneal dialysis was 8,604+/-1,721 microgram/liter. There were no significant changes of serum IGF-I and IGFBP-3 levels after long-term peritoneal dialysis. We found that the level of IGF-1 before hemodialysis was lower then that of normal control group and the level of IGFBP-3 before hemodialysis or peritoneal dialysis was higher then that of normal control group. Our results suggested that the blood levels of growth hormone, IGF-I and IGFBP-3 may not be significantly affected by long-term dialysis therapy.
Biological Availability ; Dialysis* ; Growth Hormone* ; Humans ; Insulin-Like Growth Factor Binding Protein 3 ; Insulin-Like Growth Factor Binding Proteins ; Insulin-Like Growth Factor I ; Peritoneal Dialysis ; Renal Dialysis